Cara Therapeutics (NASDAQ:CARA) will post its quarterly earnings results after the market closes on Monday, May 10th. Analysts expect Cara Therapeutics to post earnings of ($0.62) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $2.12. The business had revenue of $112.09 million for the quarter, compared to analyst estimates of $6.63 million. Cara Therapeutics had a negative return on equity of 64.36% and a negative net margin of 360.35%. On average, analysts expect Cara Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of Cara Therapeutics stock traded down $0.37 during trading on Tuesday, reaching $12.70. The company’s stock had a trading volume of 30,182 shares, compared to its average volume of 1,049,915. Cara Therapeutics has a one year low of $12.30 and a one year high of $29.65. The firm has a market cap of $635.53 million, a price-to-earnings ratio of -6.17 and a beta of 1.70. The business’s fifty day moving average price is $23.10 and its 200-day moving average price is $18.25.
In related news, insider Scott Terrillion sold 4,004 shares of the business’s stock in a transaction that occurred on Thursday, February 25th. The shares were sold at an average price of $19.33, for a total value of $77,397.32. Following the completion of the transaction, the insider now owns 48,436 shares in the company, valued at approximately $936,267.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joana Goncalves sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 21st. The stock was sold at an average price of $27.63, for a total transaction of $82,890.00. Following the completion of the transaction, the insider now owns 43,610 shares of the company’s stock, valued at approximately $1,204,944.30. The disclosure for this sale can be found here. Insiders sold 36,287 shares of company stock valued at $714,394 in the last quarter. 5.70% of the stock is currently owned by corporate insiders.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Featured Article: VIX – Volatility Index
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.